CN113710670A - 治疗多发性骨髓瘤的方法 - Google Patents

治疗多发性骨髓瘤的方法 Download PDF

Info

Publication number
CN113710670A
CN113710670A CN202080030185.4A CN202080030185A CN113710670A CN 113710670 A CN113710670 A CN 113710670A CN 202080030185 A CN202080030185 A CN 202080030185A CN 113710670 A CN113710670 A CN 113710670A
Authority
CN
China
Prior art keywords
subject
compound
multiple myeloma
pharmaceutical composition
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030185.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·L·威特尔
曹良弦
A·博洛姆斯基
H·路德维希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of CN113710670A publication Critical patent/CN113710670A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080030185.4A 2019-02-28 2020-02-26 治疗多发性骨髓瘤的方法 Pending CN113710670A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
US62/812,002 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (1)

Publication Number Publication Date
CN113710670A true CN113710670A (zh) 2021-11-26

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080030185.4A Pending CN113710670A (zh) 2019-02-28 2020-02-26 治疗多发性骨髓瘤的方法

Country Status (11)

Country Link
US (1) US20220143016A1 (https=)
EP (1) EP3931196A4 (https=)
JP (1) JP2022521801A (https=)
CN (1) CN113710670A (https=)
AU (1) AU2020227748A1 (https=)
BR (1) BR112021016747A2 (https=)
CA (1) CA3131249A1 (https=)
EA (1) EA202192117A1 (https=)
IL (1) IL285800A (https=)
MX (1) MX2021010398A (https=)
WO (1) WO2020176610A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978055A (en) * 1973-09-20 1976-08-31 Delalande S.A. Arylamino pyrimidinic derivatives
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN104918919A (zh) * 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2624818B1 (en) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
EA034866B1 (ru) * 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
EP3836932A2 (en) * 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Method for treating pancreatic cancer
US20220185795A1 (en) * 2019-03-11 2022-06-16 Ptc Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3978055A (en) * 1973-09-20 1976-08-31 Delalande S.A. Arylamino pyrimidinic derivatives
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CN104918919A (zh) * 2012-11-21 2015-09-16 Ptc医疗公司 取代的反向嘧啶Bmi-1抑制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARNOLD BOLOMSKY等: "Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, pages 1 - 13 *
余传隆 等: "《中国临床药物大辞典 化学药卷》", vol. 1, 31 August 2018, 中国医药科技出版社, pages: 861 - 862 *
徐志巧 等: "《实用肿瘤临床药物手册》", vol. 1, 30 June 2013, 中国医药科技出版社, pages: 127 - 128 *

Also Published As

Publication number Publication date
AU2020227748A1 (en) 2021-09-16
BR112021016747A2 (pt) 2021-10-19
WO2020176610A8 (en) 2021-08-12
IL285800A (en) 2021-10-31
EP3931196A4 (en) 2022-12-14
JP2022521801A (ja) 2022-04-12
CA3131249A1 (en) 2020-09-03
EA202192117A1 (ru) 2021-11-23
WO2020176610A1 (en) 2020-09-03
EP3931196A1 (en) 2022-01-05
MX2021010398A (es) 2022-01-18
US20220143016A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
US11458126B2 (en) DHODH inhibitor for use in treating hematologic cancers
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
JP2025032069A (ja) 膵臓癌を治療する方法
BR112021004935A2 (pt) combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer
KR20230031242A (ko) 골수증식성 신생물의 치료를 위한 병용 요법
CN119431581A (zh) 抗原结合蛋白
CN113710670A (zh) 治疗多发性骨髓瘤的方法
CN113784757A (zh) 治疗急性髓性白血病的方法
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
CN114096537B (zh) 肉瘤治疗方法的有用组合
CN110496223B (zh) 一种治疗非霍奇金氏淋巴瘤的药物组合物
EA047152B1 (ru) Способ лечения множественной миеломы
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination